Remlife Global PTE LTD. A Wholly Own Subsidiary of Remedium Lifecare Limited Announces Strategic Partnership with JiyaYu Lifesciences to Replace Animal-Origin Inputs in APIs and Intermediates ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare's Singapore-based subsidiary Remlife Global PTE LTD has entered a strategic partnership with JiyaYu Lifesciences, a green chemistry technology platform, to replace animal-origin raw materials in the manufacturing of APIs and advanced intermediates. JiyaYu will exclusively license scalable fermentation and biocatalyst-based technologies to Remlife Global, which will commercialise them at GMP-compliant contract manufacturing sites in India, Singapore, Malta, Ireland, Belgium, and Italy. Each technology platform has an estimated minimum commercial potential of ₹50 crore per product, with projected EBITDA margins of 20–25%. The company forecasts ₹100 crore revenue and ₹20–25 crore EBITDA in FY26 (2 products), scaling to ₹200 crore revenue and ₹40–50 crore EBITDA in FY27 (4 products). The move aligns with growing ESG, safety, and supply-chain resilience trends in global pharma.
This partnership opens a new high-margin, sustainability-driven revenue stream for Remedium Lifecare through its international subsidiary, with concrete multi-year revenue and EBITDA guidance that could materially expand the company's earnings base if executed on time. Investors should view it as a positive long-term catalyst, though actual numbers remain projections and execution risk across multiple geographies is high.